查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015171

非何傑金氏淋巴瘤治療市場：依治療方法、細胞類型、給藥途徑、患者年齡層和最終用戶分類－2026年至2032年全球市場預測

Non-Hodgkin Lymphoma Treatment Market by Treatment Type, Cell Type, Route of Administration, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非何傑金氏淋巴瘤治療市場價值將達到 36.5 億美元，到 2026 年將成長至 38.6 億美元，到 2032 年將達到 58.5 億美元，年複合成長率為 6.97%。

主要市場統計數據
基準年 2025 36.5億美元
預計年份：2026年 38.6億美元
預測年份 2032 58.5億美元
複合年成長率 (%) 6.97%

全面概述了影響非何傑金氏淋巴瘤治療策略的多方面臨床、監管和商業性因素，涵蓋所有醫療保健環境。

非何傑金氏淋巴瘤）是一組異質性極高的骨髓惡性腫瘤，持續給臨床醫生、保險公司和創新者帶來挑戰。近年來，免疫療法和標靶治療的進展，以及細胞療法的改進，重塑了許多亞型的臨床路徑。同時，診斷技術和風險分層工具的進步，使得更個人化的治療方案成為可能。本文概述了支撐研發和市場進入團隊當前策略決策的臨床、監管和商業性背景。

確定正在重新定義非何傑金氏淋巴瘤治療方法開發和引入的關鍵臨床、監管和商業性變革。

非何傑金氏淋巴瘤的治療格局正受到多種因素的共同影響而發生變革，這些因素正在改變治療方法的研發、核准和應用方式。首先，精準醫療和分子譜分析正從小眾領域走向主流，使得B細胞、T細胞和NK細胞淋巴瘤的分類更加精細，並為標靶治療策略的發展提供了依據。其次，細胞療法和雙特異性抗體的成熟拓展了根治性和維持療效的可能性，使其超越了傳統的化療和放療，促使人們重新評估治療方案和聯合治療策略。

評估 2025 年美國關稅調整對供應鏈韌性、成本管理和商業性准入策略的多方面影響。

2025年影響貿易和進口關稅的政策變化為藥品供應鏈規劃、定價策略和跨境臨床試驗物流引入了新的變數。關稅調整可能會影響活性藥物成分、成品生技藥品和醫療設備的接收成本，促使製造商重新評估籌資策略和庫存佈局。為此，各組織正在加快加強供應鏈韌性的步伐，包括採用雙重採購、關鍵零件近岸外包以及策略性儲備，以降低供應鏈中斷和成本增加的風險。

整合治療方法、細胞亞型、給藥途徑、病患年齡層和醫療保健服務環境的實用細分見解。

精準理解臨床和商業領域對於將研發項目和商業化計劃與未滿足的醫療需求和治療路徑相匹配至關重要。基於治療類型的分析涵蓋化療、免疫療法、放射線治療、幹細胞移植和標靶治療，並檢視每種治療方法在治療順序、相容性和耐受性方面如何與現代治療方法相互作用。基於細胞類型，區分B細胞淋巴瘤、NK細胞淋巴瘤和T細胞淋巴瘤是策略的核心。 B細胞淋巴瘤進一步分為伯基特淋巴瘤、瀰漫性大B細胞淋巴瘤（DLBCL）、濾泡性淋巴瘤、套細胞淋巴瘤和周邊區域淋巴瘤，而T細胞淋巴瘤則進一步分為異生性大細胞淋巴瘤、皮膚T細胞淋巴瘤和周邊T細胞淋巴瘤。每種淋巴瘤都有其獨特的治療需求和臨床試驗考量。

詳細的區域洞察，揭示美洲、歐洲、中東、非洲和亞太地區的監管細微差別、證據優先事項和准入途徑。

區域趨勢在決定非何傑金氏淋巴瘤治療的監管策略、臨床開發重點和商業化路徑方面發揮著至關重要的作用。在美洲，監管和支付系統結合了快速核准機制和嚴格的醫療技術評估流程，因此需要重點關注兩方面：突破性認定策略和可靠的真實世界證據。在歐洲、中東和非洲，由於法規環境的多樣性和准入差異，需要製定個人化的市場准入計劃、適應性定價策略和區域夥伴關係，以最佳化市場滲透率和患者可及性。

戰略競爭情報概述了成熟的製藥集團和敏捷的創新者如何透過證據、夥伴關係和交付模式來脫穎而出。

非何傑金氏淋巴瘤治療領域的競爭格局呈現出兩極化的特點：既有老牌腫瘤主要企業，也有積極創新、不斷推出新治療方法的企業。儘管老牌製藥公司在後期研發、全球商業化和生產規模化方面仍然發揮著至關重要的作用，但規模小規模的生物技術公司往往在雙特異性抗體、抗體藥物複合體物（ADC）和細胞療法平台等早期創新領域佔據主導地位。合作、授權和策略聯盟十分常見，這使得靈活的公司能夠利用大型合作夥伴在監管和商業化方面的專業知識，而老牌公司則可以利用創新的作用機制來更新其產品線。

為行業領導者提供切實可行的優先建議，以協調臨床開發、證據生成和打入市場策略，從而取得永續的成果。

行業領導者應優先考慮將科學研發與商業化和市場準備相結合的整合策略。首先，應儘早投資於可靠的生物標記和診斷策略，以確保選擇合適的患者，並提高獲得監管部門核准和醫療保險報銷的可能性。其次，應制定實證方案，結合隨機對照試驗、前瞻性真實世界研究和衛生經濟學分析，為獲得監管部門核准和有利的醫保報銷決策提供支援。第三，應透過採購多元化、靈活的生產結構和緊急時應對計畫來增強供應鏈韌性，以緩解政策帶來的成本壓力和物流中斷。

採用透明、多方面的研究方法，將二次調查與和關鍵相關人員的直接對話結合，以檢驗臨床和商業性發現。

本報告的研究結合了全面的二手資料分析和有針對性的一手調查，以確保研究的嚴謹性和相關性。二手資料包括同儕審查的臨床文獻、監管指導文件、臨床試驗註冊資訊和支付方政策文件，這些資料被整合起來，以揭示臨床路徑、核准情況和證據方面的不足。一手研究包括對關鍵意見領袖（KOL）、主治醫生、支付方和患者權益倡導組織代表進行結構化訪談，以了解他們對治療偏好、應用障礙和未滿足需求的細緻觀點。

本摘要重點介紹了綜合證據、營運靈活性和相關人員參與如何決定非何傑金氏淋巴瘤。

非何傑金氏淋巴瘤的治療正處於十字路口，標靶治療、免疫療法和更精準的診斷框架是推動治療發展的關鍵因素。這些進展雖然有望改善患者預後並重新定義治療標準，但也帶來了證據要求、定價爭議和營運準備的複雜性。要成功應對這種情況，需要製定一項涵蓋研發、監管合作、支付方參與和醫療機構部署等各個環節的協調策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章非何傑金氏淋巴瘤治療市場（依治療方法分類）

  • 化療
  • 免疫療法
  • 放射線治療
  • 幹細胞移植
  • 分子標靶治療

第9章非何傑金氏淋巴瘤治療市場（依細胞類型分類）

  • B細胞淋巴瘤
    • 伯基特淋巴瘤
    • 瀰漫性大B細胞淋巴瘤（DLBCL）
    • 濾泡性淋巴瘤
    • 套細胞淋巴瘤
    • 周邊區域淋巴瘤
  • NK細胞淋巴瘤
  • T細胞淋巴瘤
    • 異生性大細胞淋巴瘤
    • 皮膚T細胞淋巴瘤
    • 周邊T細胞淋巴瘤

第10章非何傑金氏淋巴瘤治療市場：依給藥途徑分類

  • 靜脈注射
  • 口服
  • 皮下注射

第11章 按患者年齡層別分類的非何傑金氏淋巴瘤治療市場

  • 成人版
  • 老年人
  • 兒童

第12章非何傑金氏淋巴瘤治療市場：依最終用戶分類

  • 門診手術中心
  • 癌症治療中心
  • 醫院

第13章非何傑金氏淋巴瘤治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章非何傑金氏淋巴瘤治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章非何傑金氏淋巴瘤治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國非何傑金氏淋巴瘤治療市場

第17章：中國非何傑金氏淋巴瘤治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals
Product Code: MRR-036C5CF3B518

The Non-Hodgkin Lymphoma Treatment Market was valued at USD 3.65 billion in 2025 and is projected to grow to USD 3.86 billion in 2026, with a CAGR of 6.97%, reaching USD 5.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.65 billion
Estimated Year [2026] USD 3.86 billion
Forecast Year [2032] USD 5.85 billion
CAGR (%) 6.97%

A comprehensive orientation to the multifaceted clinical, regulatory, and commercial forces shaping Non-Hodgkin Lymphoma treatment strategies across care settings

Non-Hodgkin Lymphoma represents a diverse group of hematologic malignancies that continues to challenge clinicians, payers, and innovators in equal measure. Recent advances in immunotherapies, targeted agents, and refinements in cellular therapies have rewritten clinical pathways for many subtypes, while diagnostic improvements and risk stratification tools are enabling more personalized approaches to care. This introduction establishes the clinical, regulatory, and commercial context that underpins current strategic decision-making across research, development, and market access teams.

The evolving treatment paradigm has created opportunities and complexities across care settings, prompting multidisciplinary collaboration among oncologists, hematologists, and allied specialists. Health systems are grappling with integrating high-cost, high-impact therapies into existing formularies and care pathways, and payers are increasingly focused on real-world evidence and value-based arrangements. Consequently, stakeholders must navigate shifting reimbursement environments, regulatory pathways that prioritize accelerated approvals, and competitive dynamics driven by novel mechanisms of action. This section sets the stage for the deeper analysis that follows, highlighting the intersections of clinical innovation and commercial readiness that will shape near-term strategy.

Identifying the pivotal clinical, regulatory, and commercial transformations that are redefining therapeutic development and adoption in Non-Hodgkin Lymphoma care

The landscape for Non-Hodgkin Lymphoma treatment is being transformed by several convergent forces that are altering how therapies are developed, approved, and adopted. First, precision medicine and molecular profiling have moved from niche to mainstream, enabling more granular classification of B-cell, T-cell, and NK-cell lymphomas and informing targeted therapeutic approaches. Second, the maturation of cellular therapies and bispecific antibodies is expanding curative and durable response possibilities beyond traditional chemotherapy and radiation, prompting a re-evaluation of sequencing and combination strategies.

Simultaneously, regulatory frameworks are evolving to accommodate accelerated pathways and conditional approvals, increasing the importance of post-approval evidence generation. Health technology assessment processes are adapting to novel endpoints and patient-reported outcomes, which is reshaping evidence generation plans. On the commercial front, partnerships between biotech innovators and established pharmaceutical companies are accelerating late-stage development and global commercialization, while digital therapeutics and telehealth are enhancing patient monitoring and survivorship care. Taken together, these shifts demand integrated strategies that span clinical development, real-world evidence, pricing, and stakeholder engagement to realize the full potential of new therapies.

Evaluating the multifaceted repercussions of United States tariff adjustments in 2025 on supply chain resilience, cost management, and commercial access strategies

Policy changes affecting trade and import tariffs in 2025 have introduced new variables into planning for drug supply chains, pricing strategies, and cross-border clinical trial logistics. Tariff adjustments can influence the landed cost of active pharmaceutical ingredients, finished biologics, and medical devices, leading manufacturers to reassess sourcing strategies and inventory positioning. In response, organizations are accelerating supply-chain resilience efforts, including dual-sourcing, nearshoring of critical components, and strategic stockpiling to mitigate the potential for disruption and cost escalation.

Beyond direct cost impacts, tariffs influence commercial strategies by altering net pricing calculations and reimbursement negotiations across payers and providers. Pharmaceutical companies are increasingly engaging in scenario planning to understand how incremental tariff-driven cost pressures could affect contract negotiations and tender outcomes. Additionally, cross-border collaborations in clinical development and manufacturing are being reevaluated to minimize exposure to tariff volatility. The cumulative effect is a heightened emphasis on flexible manufacturing, diversified supplier networks, and proactive stakeholder communication to preserve access and maintain the continuity of care for patients with Non-Hodgkin Lymphoma.

Actionable segmentation insights that integrate treatment modalities, cellular subtypes, administration routes, patient age demographics, and healthcare delivery settings

A precise understanding of clinical and commercial segments is essential to align development programs and commercial launch plans with unmet need and care pathways. Based on Treatment Type, analysis considers Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell Transplant, and Targeted Therapy and how each modality interacts with sequencing, combinability, and tolerability in contemporary regimens. Based on Cell Type, differentiation among B-cell Lymphomas, NK-cell Lymphomas, and T-cell Lymphomas is central to strategy, with B-cell Lymphomas further broken down into Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, and Marginal Zone Lymphoma, and T-cell Lymphomas further categorized into Anaplastic Large Cell Lymphoma, Cutaneous T-Cell Lymphoma, and Peripheral T-Cell Lymphoma, each presenting distinct therapeutic needs and clinical trial considerations.

Based on Route of Administration, distinctions between Intravenous Infusion, Oral, and Subcutaneous Injection influence patient preference, adherence, and site-of-care economics. Based on Patient Age Group, the adult, geriatric, and pediatric populations exhibit varying comorbidity profiles, tolerability constraints, and long-term survivorship considerations that should inform dosing strategies and safety monitoring plans. Based on End User, differences in care delivery across Ambulatory Surgical Centers, Cancer Treatment Centers, and Hospitals affect reimbursement pathways, capacity planning, and clinician adoption patterns. Integrating these segmentation layers enables targeted clinical development, differentiated value propositions, and nuanced go-to-market planning.

Deep regional intelligence highlighting regulatory nuance, evidence priorities, and access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a critical role in shaping regulatory strategies, clinical development priorities, and commercialization pathways for Non-Hodgkin Lymphoma therapies. In the Americas, regulatory authorities and payer systems present a mix of accelerated approval mechanisms and rigorous health technology assessment processes, driving a dual focus on breakthrough designation strategies and robust real-world evidence generation. In Europe, Middle East & Africa, heterogeneous regulatory environments and disparities in access necessitate tailored market entry plans, adaptive pricing strategies, and regional partnerships to optimize uptake and patient access.

In the Asia-Pacific region, rapid expansion of clinical research capacity, growing domestic biopharma innovation, and evolving reimbursement frameworks are creating both opportunity and complexity. Local manufacturing, regional clinical trial networks, and government-led initiatives to improve cancer outcomes are shaping pathways to adoption. Across all regions, cross-border collaboration, regulatory harmonization efforts, and the localization of evidence packages are increasingly important to ensure timely approval and sustainable access. Understanding these regional nuances is essential for designing regulatory submission strategies, evidence generation plans, and commercial approaches that are responsive to local healthcare infrastructures and payer expectations.

Strategic competitive intelligence outlining how incumbent pharmaceutical groups and nimble innovators are shaping differentiation through evidence, partnerships, and delivery models

Competitive dynamics in Non-Hodgkin Lymphoma treatment are characterized by a blend of legacy oncology players and agile innovators advancing novel modalities. Established pharmaceutical companies remain critical in late-stage development, global commercialization, and manufacturing scale-up, while smaller biotechs often drive early innovation in bispecifics, ADCs, and cellular platforms. Collaborations, licensing deals, and strategic alliances are common, enabling nimble companies to leverage larger partners' regulatory and commercial expertise and enabling incumbents to refresh pipelines with innovative mechanisms of action.

The competitive landscape also reflects differentiation through evidence generation strategies, including pivotal trials focused on durable endpoints, real-world evidence programs to demonstrate effectiveness in broader populations, and biomarker-driven development to improve patient selection. Manufacturers are investing in patient support programs, hub services, and digital health tools to optimize adherence and streamline administration. As competition intensifies, companies that can demonstrate clear clinical differentiation, robust safety profiles, and pragmatic implementation models across diverse care settings will be positioned to capture clinician preference and payer support.

Practical and prioritized recommendations for industry leaders to synchronize clinical development, evidence generation, and market access strategies for durable impact

Industry leaders should prioritize an integrated strategy that aligns scientific development with commercial and access readiness. First, invest in robust biomarker and diagnostics strategies early to ensure precise patient selection and to improve the probability of regulatory success and payer acceptance. Second, design evidence-generation plans that combine randomized trials with prospective real-world studies and health economics analyses to support both regulatory approval and favorable reimbursement decisions. Third, strengthen supply chain resilience through diversified sourcing, flexible manufacturing, and contingency planning to mitigate policy-driven cost pressures and logistical disruptions.

In parallel, develop differentiated value propositions that articulate not only clinical benefits but also system-level value such as reduced hospitalizations and improved quality of life. Engage early with payers, HTA bodies, and provider networks to co-create reimbursement pathways, including outcomes-based arrangements where appropriate. Finally, foster partnerships across the ecosystem-academic centers, contract manufacturers, diagnostics providers, and patient advocacy organizations-to accelerate evidence generation and streamline adoption. These combined actions will help organizations translate therapeutic innovation into durable clinical and commercial impact.

Transparent multi-method research approach combining secondary synthesis and primary stakeholder engagement to validate clinical and commercial insights

The research underpinning this report combines comprehensive secondary analysis with targeted primary engagements to ensure rigor and relevance. Secondary inputs include peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and payer policy publications, all synthesized to map clinical pathways, approval landscapes, and evidence gaps. Primary research incorporates structured interviews with key opinion leaders, treating physicians, payers, and patient advocacy representatives to capture nuanced perspectives on treatment preferences, barriers to adoption, and unmet needs.

Data triangulation methods were applied to reconcile divergent inputs and validate thematic conclusions. Analytical techniques included cross-validation of clinical outcomes with real-world treatment patterns, assessment of regulatory precedents against current development programs, and synthesis of commercial strategies through case-based benchmarking. Quality controls included independent expert review and an internal verification process to ensure consistency and transparency. This mixed-method approach ensures that the insights presented are grounded in clinical reality, reflective of stakeholder priorities, and actionable for strategic decision-making.

Concluding synthesis highlighting how integrated evidence, operational agility, and stakeholder engagement will determine the pace of therapeutic impact in Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma treatment is at a transformative juncture driven by targeted therapies, immunologic approaches, and more precise diagnostic frameworks. These advances offer the potential to improve patient outcomes and redefine standard-of-care sequences, yet they also introduce complexities in evidence requirements, pricing discussions, and operational readiness. Successful navigation will require coordinated strategies across development, regulatory engagement, payer interactions, and provider adoption efforts.

Looking ahead, organizations that embrace integrated evidence generation, invest in supply chain agility, and actively engage stakeholders across regions will be better positioned to translate innovation into sustainable clinical impact. The convergence of scientific progress and changing commercial dynamics presents both opportunities and responsibilities: to design therapies that meet unmet needs, to generate the evidence required for broad access, and to implement delivery models that ensure equitable patient benefit. This conclusion underscores the imperative for strategic alignment and timely action to realize the promise of new treatments for patients living with Non-Hodgkin Lymphoma.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Radiation Therapy
  • 8.4. Stem Cell Transplant
  • 8.5. Targeted Therapy

9. Non-Hodgkin Lymphoma Treatment Market, by Cell Type

  • 9.1. B-cell Lymphomas
    • 9.1.1. Burkitt Lymphoma
    • 9.1.2. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 9.1.3. Follicular Lymphoma
    • 9.1.4. Mantle Cell Lymphoma
    • 9.1.5. Marginal Zone Lymphoma
  • 9.2. NK-cell Lymphomas
  • 9.3. T-cell Lymphomas
    • 9.3.1. Anaplastic Large Cell Lymphoma
    • 9.3.2. Cutaneous T-Cell Lymphoma
    • 9.3.3. Peripheral T-Cell Lymphoma

10. Non-Hodgkin Lymphoma Treatment Market, by Route of Administration

  • 10.1. Intravenous Infusion
  • 10.2. Oral
  • 10.3. Subcutaneous Injection

11. Non-Hodgkin Lymphoma Treatment Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Non-Hodgkin Lymphoma Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cancer Treatment Centers
  • 12.3. Hospitals

13. Non-Hodgkin Lymphoma Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Non-Hodgkin Lymphoma Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Non-Hodgkin Lymphoma Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Non-Hodgkin Lymphoma Treatment Market

17. China Non-Hodgkin Lymphoma Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. BeiGene, Ltd.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Cipla Inc.
  • 18.11. Dr. Reddy's Laboratories Ltd.
  • 18.12. Eli Lilly and Company
  • 18.13. F. Hoffmann-La Roche Ltd
  • 18.14. Gilead Sciences, Inc.
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Hikma Pharmaceuticals PLC
  • 18.17. Intas Pharmaceuticals Ltd.
  • 18.18. Kyowa Kirin Co., Ltd.
  • 18.19. Lupin Ltd.
  • 18.20. Merck & Co., Inc.
  • 18.21. Novartis AG
  • 18.22. Salvavidas Pharmaceutical Pvt. Ltd.
  • 18.23. Sanofi S.A.
  • 18.24. Takeda Pharmaceutical Company Limited
  • 18.25. Teva Pharmaceutical Industries Ltd.
  • 18.26. Zydus Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)